Posaconazole Pharmacokinetics in Adults with Invasive Fungal Infections

Posaconazole Pharmacokinetics in Adults with Invasive Fungal InfectionsWed, 01/03/2018 - 15:39News blog
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news

Related Links:

Authors: Hagiwara D Abstract Aspergillus fumigatus is a saprophytic fungus that is a major causative pathogen for aspergillosis. Only a few classes of antifungals are used for treating this life-threatening fungal infection. Azoles are the first-line drugs and are widely used for the management and prophylaxis of aspergillosis. An emerging issue is the increasing incidence of resistant isolates worldwide. In particular, environmentally derived tandem-repeat-type azole-resistant mutations, such as Cyp51A TR34/L98H, and Cyp51A TR46/Y121F/T289A, have emerged over the last decade. In particular, azole-resistant isolate...
Source: Medical Mycology Journal - Category: Biology Tags: Med Mycol J Source Type: research
Publication date: Available online 4 December 2018Source: The Journal of Molecular DiagnosticsAuthor(s): Ling-Shan Yu, Jesus Rodriguez-Manzano, Kenny Malpartida-Cardenas, Thomas Sewell, Oliver Bader, Darius Armstrong-James, Matthew C. Fisher, Pantelis GeorgiouAbstractInvasive human fungal infections caused by multi-azole resistant Aspergillus fumigatus are associated with increasing rates of mortality in susceptible patients. Current methods of diagnosing infections caused by multi-azole resistant A. fumigatus are, however, not well suited for use in clinical point-of-care testing or in the field. Loop-mediated isothermal ...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
CONCLUSION: Our results showed that the proposed polyphasic approach appears to be a useful strategy in the detection of fungi from tissue samples, allowing a better prognosis. In further studies, the inclusion of a higher number of samples and the implementation of more genus-specific PCRs will certainly contribute to an increase in the specificity and sensitivity of this method. PMID: 30480509 [PubMed - as supplied by publisher]
Source: Journal of Medical Microbiology - Category: Microbiology Authors: Tags: J Med Microbiol Source Type: research
Analyst, 2019, Advance Article DOI: 10.1039/C8AN01591K, PaperG örkem Bakir, Benoit E. Girouard, Robert W. Johns, Catherine R.-J. Findlay, Hans A. Bechtel, Max Eisele, Susan G. W. Kaminskyj, Tanya E. S. Dahms, Kathleen M. Gough With lethal opportunistic fungal infections on the rise, it is imperative to explore new methods to examine virulence mechanisms. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Analyst latest articles - Category: Chemistry Authors: Source Type: research
This four-week course is intended for microbiologists (MDs, PharmDs, PhDs&veterinarians)  willing to catch up with the most recent advances in diagnosis and identification procedures and principles of therapy for fungal infections.Courses&Workshops
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Source Type: news
Administration of azoles, like fluconazole, in the treatment of difficult-to-treat fungal infections in pregnant women have been correlated with observations of congenital abnormalities in infants exposed in utero. Here we present developmental and reproductive toxicity data for a novel triterpenoid glucan synthase inhibitor, SCY-078, with proven anti-fungal activity against Candida, Aspergillus and Pneumocystis spp. currently in clinical development for the treatment of Vulvovaginal Candidiasis (VVC) and other severe invasive fungal infections.
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: IDSOG Abstract Source Type: research
Conclusions: These results demonstrate ISAV to be a safe and effective alternative for antifungal ppx in treatment-naïve pts with AML/MDS undergoing induction therapy with a variety of different regimens. ISAV's weak inhibition of P-glycoprotein and lack of risk of QT prolongation may make ISAV particularly attractive for antifungal ppx in the era of recently approved or emerging AML therapies such as enasidenib, ivosidenib, midostaurin and quizartinib.DisclosuresBose: CTI BioPharma: Research Funding; Constellation Pharmaceuticals: Research Funding; Blueprint Medicines Corporation: Research Funding; Celgene Corporatio...
Source: Blood - Category: Hematology Authors: Tags: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II Source Type: research
Conclusions. ISV is widely used in hematological pts with IFI also in diseases other than acute myeloid leukemia and it is overall well tolerated. ORR to ISV is at least comparable with other antifungal agents. A rec/ref underlying hematological disease impacts both on OS and response to ISV, while having an IFI refractory to other antifungal agents including azoles does not seem to compromise the response to ISV, although this promising result should be confirmed in prospective studies and larger groups of patients.DisclosuresBusca: Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Sp...
Source: Blood - Category: Hematology Authors: Tags: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster III Source Type: research
CONCLUSION: Polyene prophylaxis offers effective antifungal activity with improved tolerability compared to older agents. The potential impact of this treatment should be included in current prophylaxis guidelines of antileukemic treatment.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster III Source Type: research
ConclusionIFI occurred in 9.6% of patients treated with HMA, but was observed in 20.4% of those who were neutropenic on C1D1 of HMA. Another potential risk factor identified was t-MDS versus de novo MDS. Prospective evaluation of mold-active antifungal prophylaxis in patients with MDS or AML who are neutropenic at the start of HMA therapy is warranted.DisclosuresFrey: Novartis: Consultancy; Servier Consultancy: Consultancy. Perl: Arog: Consultancy; NewLink Genetics: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Astellas: Con...
Source: Blood - Category: Hematology Authors: Tags: 637. Myelodysplastic Syndromes-Clinical Studies Source Type: research
More News: Aspergillus | Blogging | Fungal Infections | Respiratory Medicine | Websites